AEON Biopharma, Inc. (AEON)

ASE – Real vaqt narxi. Valyuta: USD

0.72

+0.03 (4.62%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

0.70

-0.02 (-2.47%)

Bozordan keyin: Jun 26, 2026, 7:36 PM EDT

04.06.2026

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the presentation of new analytical and functional data supporting biosimilarity of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society (“AHS”), being held June 4-7, 2026 in Orlando, Florida. The poster is being presented by Chad K. Oh, M.D., AEON's Chief Medical Officer.

14.05.2026

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

- Reported positive FDA Type 2a meeting supporting ABP-450's comparative analytical strategy under the 351(k) regulatory pathway - - Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90% - - Bolstered leadership team with appointment of John Bencich as Chief Financial Officer - IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, reported today its financial results for the first quarter ended March 31, 2026, and provided a corporate update.

24.04.2026

AEON Biopharma Sets Annual Shareholder Meeting

- Annual Shareholder Meeting to be held at 10:00 am PT on June 17, 2026 - IRVINE, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that its Annual Shareholder Meeting will be held at 10:00 am Pacific Time (PT) on Wednesday, June 17, 2026 and will be held in the Company's offices at 5 Park Plaza, Suite 1750, Irvine, CA 92614.

03.04.2026

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that, on April 2, 2026, in connection with the appointment of John Bencich as Chief Financial Officer, the Company's Compensation Committee of the Board of Directors (the “Compensation Committee”) approved the grant of inducement awards.

03.04.2026

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that on March 31, 2026, it received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that, following its year-end financial results, the Company is not in compliance with an additional continued listing standard set forth in the NYSE American Company Guide (the “Company Guide”).

30.03.2026

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Prog

21.01.2026

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

- AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes - - Separately, AEON shareholders today voted in favor of the proposals required to complete the transactions announced in November, including the consummation of the PIPE financing and the related Daewoong note exchange - IRVINE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA), today reported on two separate positive events for the Company: AEON confirmed that earlier today it held its scheduled BPD Type 2a meeting with FDA, in line with prior guidance.

Videolar

No Data

There is no data to display

Press-relizlar

14.05.2026

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

24.04.2026

AEON Biopharma Sets Annual Shareholder Meeting

03.04.2026

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

03.04.2026

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that on March 31, 2026, it received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that, following its year-end financial results, the Company is not in compliance with an additional continued listing standard set forth in the NYSE American Company Guide (the “Company Guide”).

AEON Biopharma, Inc. (AEON)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AEON Biopharma, Inc. (AEON)

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

AEON Biopharma Sets Annual Shareholder Meeting

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

Videolar

No Data

Press-relizlar

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

AEON Biopharma Sets Annual Shareholder Meeting

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

AEON Biopharma Sets Annual Shareholder Meeting

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

Videolar

No Data

Press-relizlar

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

AEON Biopharma Sets Annual Shareholder Meeting

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

Search stocks

AEON Biopharma, Inc. (AEON)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AEON Biopharma, Inc. (AEON)

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

AEON Biopharma Sets Annual Shareholder Meeting

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

Videolar

No Data

Press-relizlar

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

AEON Biopharma Sets Annual Shareholder Meeting

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

AEON Biopharma Sets Annual Shareholder Meeting

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

Videolar

No Data

Press-relizlar

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

AEON Biopharma Sets Annual Shareholder Meeting

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards